Charles river to perform plasmid manufacturing for aavantgarde

Wilmington, mass.--(business wire)--charles river laboratories international, inc. (nyse: crl) and aavantgarde today announced a contract development and manufacturing organization (cdmo) agreement to produce good manufacturing practice- (gmp) plasmid dna. aavantgarde, a clinical-stage biotechnology company with two proprietary adeno-associated viral (aav) vector platforms for large gene delivery and developing products to treat inherited retinal diseases, will leverage charles river's expertis.
CRL Ratings Summary
CRL Quant Ranking